Top business and operational executive for a NASDAQ-listed Radiopharmaceutical Oncology biotech. Key responsibilities include: Business Development and Alliance Management; Development Portfolio & Program Management; Financing, IR and Shareholder/Board management; Commercial Operations

Executive Director, CML Lead (TASIGNA®, Asciminib & GLIVEC®)WorldWide Commercial lead for CML franchise - TASIGNA® (~$2B Oncology product), launch lead for Asciminib (ABL001) and GLIVEC®

Led US marketing & sales efforts for COSENTYX Brand Strategy, sales force optimization, competitive preparation, customer engagement, market access & patient services etc.• Led the development of US integrated brand strategy and developed tactical plan with key cross-functional partners to drive ~50% topline growth • Spearheaded physician segmentation and positioning to customize selling approach to increase ~30% breadth & depth; led physician research, developed strategies & training materials with the field and led roll-out and execution• Led field force expansion efforts to increase Cosentyx breadth, developed the business case, finalized targeting, alignment and field rollout• Developed launch readiness strategy and cross-functional action-plan for key competitor entering the market to protect key source of business• Brand lead for Strategic Plan, budget planning, investment trade-offs and business reviews with senior leadership

Led pipeline teams, product development strategy, market access & Business Development deals in multiple indications• Led commercial & financial assessments for licensing deals and mandates for multiple cardio-metabolic diseases• Defined Novartis strategy for highly competitive NASH market; identified high-value patient segments, optimal trial endpoints, market access levers, and need for diagnostic and capability building for success in a de-novo market • Led pipeline and access team for Ph2/3 asset for NASH/liver indications (#1 portfolio asset for hepatology); defined value proposition, commercial strategy, indication sequencing and financial opportunity for approval by CEO• Led the pipeline team (marketing, pricing & access, HEOR) for Ph 1/2 asset for multiple CV indications; defined commercial & access strategy, built P&L with regions and achieved successful CEO approval • Devised comprehensive patient solutions for initiation, monitoring and physician feedback for new pipeline asset

Led multiple asset/brand teams to maximize value of new launch and pipeline products in Oncology, Neuroscience and Immunology and interfaced with senior executives and governance bodies • Responsible for ensuring optimal commercialization and strategic decision making for multiple pre-launch products in Immunology (dermatology, rheumatology, gastro) and Neuroscience franchises• Led an oral selective JAK-inhibitor product in Immunology, developing strategy and differentiated product profile to address unmet needs, defining optimal positioning in the competitive space and refining pricing & access strategy• Led a launch MS blockbuster product (ZINBRYTA) in conjunction with partner; developed differentiated positioning, strategic imperatives and target claims, built disease awareness team and initiated launch planning and safety monitoring strategy• Helped refine Immunology (Derm, RA) strategy including competitive differentiation and treatment process, key unmet needs, value proposition and positioning of target profiles, prioritization of new products and market potential• Implementation of ‘Asset Playbook’ outlining key commercial and strategic activities to achieve successful broad commercial and regulatory launch (e.g., market opportunity, TPP, value proposition, optimized clinical program etc.)• Managed a 1st-in-class product in neuroscience to refine development options for Ph III, incorporate input from KOLs & payers to refine product strategy and business case and evaluated potential partnership opportunities

Led healthcare client projects and teams across marketing, business development, strategy, M&A and operationsBusiness development and due diligence • Managed a team of 5 consultants to prepare a ~$1Bn bid proposal for the CEO of a specialty pharma company• Led a late stage licensing transaction for a ~$600M specialty product for a mid-sized pharmaco• Evaluated licensing & acquisition opportunities across oncology, immunology, neuro and other specialty diseases• Formulated biosimilar strategy and defined clinical & commercial plans for top 10 oncology and immunology targets • Conducted diligence for top products and potential synergy assessment for a pharma acquisition target• Developed overview of companion diagnostic market for pharma client and evaluated potential entry opportunitiesNew Product strategy, commercialization and launch• Optimized development and commercialization of multiple pipeline products including disease & indication prioritization, trial design refinement, market assessment and strategic positioning to maximize asset value• Established strategic brand positioning and launch strategy for a $2B blockbuster product with multiple indications • Revamped brand strategy and conducted root cause analysis for an underperforming ~$400M specialty brand; performed market research, updated targeting plan and designed 6 commercial pilots for brand turnaround• Developed a short and long term strategic plan for a key Business Unit for top specialty pharmaco• Formulated action plan for pharma, health insurers and hospitals to minimize the impact of healthcare reform bill R&D and clinical development• Led a full transformation of an R&D organization, realized trial savings of ~30% and identified capability gaps• Prioritized R&D pipeline and built risk-based forecasts and return metrics to reallocate ~$5Bn R&D budget• Identified opportunities for Big Data applications in global public health, disease monitoring and interventions

Led the efforts for establishment of a diabetes diagnostic and CV device company

Sourced, evaluated and executed lifescience investments for a $350M global venture capital/growth equity fund• Deal Execution; Deal Sourcing / Due Diligence; Innovative Investment Model

* M&A Advisory and Equity/Debt Financing

Led marketing, brand planning and launch execution initiatives supporting high priority launch and pipeline brands

Managed the strategic, business & operational activities for a 600-person group for drug, devices and delivery systems

Led the financial planning of development costs and FTEs for the portfolio of development and in-licensed projects• Successfully managed budget of $200M with team of 10 controllers for resource planning & prioritization decisions